{
  "disease_name": "Chronic visceral acid sphingomyelinase deficiency",
  "orpha_code": "77293",
  "drugs": [
    {
      "name": "Ursodeoxycholic acid",
      "substance_url": "/en/drug/substance/25078?name=77293&mode=orpha&region=&status=all",
      "substance_id": "25078",
      "regulatory_url": "/en/drug/regulatory/489675?name=77293&mode=orpha&region=",
      "regulatory_id": "489675",
      "orpha_substance_code": "ORPHA:77293",
      "details": [
        "Ursodeoxycholic acid(Medicinal product                        - 22/05/2017)Disease(s) concernedORPHA:646 Niemann-Pick disease type CORPHA:77292 Infantile neurovisceral acid sphingomyelinase deficiencyORPHA:77293 Chronic visceral acid sphingomyelinase deficiency",
        "Ursodeoxycholic acid(Medicinal product                        - 22/05/2017)",
        "(Medicinal product                        - 22/05/2017)",
        "Disease(s) concernedORPHA:646 Niemann-Pick disease type CORPHA:77292 Infantile neurovisceral acid sphingomyelinase deficiencyORPHA:77293 Chronic visceral acid sphingomyelinase deficiency",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/25078?name=77293&mode=orpha&region=&status=all",
          "text": "Ursodeoxycholic acid",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/646",
          "text": "ORPHA:646 Niemann-Pick disease type C",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/77292",
          "text": "ORPHA:77292 Infantile neurovisceral acid sphingomyelinase deficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/77293",
          "text": "ORPHA:77293 Chronic visceral acid sphingomyelinase deficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/489675?name=77293&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "type C\n                                \n\n\n\n\n                                    ORPHA:77292 Infantile neurovisceral acid sphingomyelinase deficiency\n                                \n\n\n\n\n                                    ORPHA:77293 Chronic visceral acid sphingomyelinase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US",
        "EU"
      ]
    },
    {
      "name": "Acetylleucine",
      "substance_url": "/en/drug/substance/479413?name=77293&mode=orpha&region=&status=all",
      "substance_id": "479413",
      "regulatory_url": "/en/drug/regulatory/487840?name=77293&mode=orpha&region=",
      "regulatory_id": "487840",
      "orpha_substance_code": "ORPHA:77293",
      "details": [
        "Acetylleucine(Medicinal product                        - 20/03/2017)Disease(s) concernedORPHA:646 Niemann-Pick disease type CORPHA:77292 Infantile neurovisceral acid sphingomyelinase deficiencyORPHA:77293 Chronic visceral acid sphingomyelinase deficiency",
        "Acetylleucine(Medicinal product                        - 20/03/2017)",
        "(Medicinal product                        - 20/03/2017)",
        "Disease(s) concernedORPHA:646 Niemann-Pick disease type CORPHA:77292 Infantile neurovisceral acid sphingomyelinase deficiencyORPHA:77293 Chronic visceral acid sphingomyelinase deficiency",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/479413?name=77293&mode=orpha&region=&status=all",
          "text": "Acetylleucine",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/646",
          "text": "ORPHA:646 Niemann-Pick disease type C",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/77292",
          "text": "ORPHA:77292 Infantile neurovisceral acid sphingomyelinase deficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/77293",
          "text": "ORPHA:77293 Chronic visceral acid sphingomyelinase deficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/487840?name=77293&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "type C\n                                \n\n\n\n\n                                    ORPHA:77292 Infantile neurovisceral acid sphingomyelinase deficiency\n                                \n\n\n\n\n                                    ORPHA:77293 Chronic visceral acid sphingomyelinase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US",
        "EU"
      ]
    },
    {
      "name": "Olipudase alfa",
      "substance_url": "/en/drug/substance/225655?name=77293&mode=orpha&region=&status=all",
      "substance_id": "225655",
      "regulatory_url": "/en/drug/regulatory/133739?name=77293&mode=orpha&region=",
      "regulatory_id": "133739",
      "orpha_substance_code": "ORPHA:77293",
      "details": [
        "Olipudase alfa(Medicinal product                        - 19/09/2001)Disease(s) concernedORPHA:77293 Chronic visceral acid sphingomyelinase deficiency",
        "Olipudase alfa(Medicinal product                        - 19/09/2001)",
        "(Medicinal product                        - 19/09/2001)",
        "Disease(s) concernedORPHA:77293 Chronic visceral acid sphingomyelinase deficiency",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/225655?name=77293&mode=orpha&region=&status=all",
          "text": "Olipudase alfa",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/77293",
          "text": "ORPHA:77293 Chronic visceral acid sphingomyelinase deficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/133739?name=77293&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "XENPOZYME",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/629878?name=77293&mode=orpha&region=",
      "regulatory_id": "629878",
      "orpha_substance_code": "ORPHA:618899",
      "details": [
        "XENPOZYME(Tradename                        - 24/06/2022)Disease(s) concernedORPHA:618899 Acid sphingomyelinase deficiency",
        "XENPOZYME(Tradename                        - 24/06/2022)",
        "(Tradename                        - 24/06/2022)",
        "Disease(s) concernedORPHA:618899 Acid sphingomyelinase deficiency",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/629877?name=77293&mode=orpha&region=&status=all",
          "text": "XENPOZYME",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/618899",
          "text": "ORPHA:618899 Acid sphingomyelinase deficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/629878?name=77293&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "PLERIXAFOR ACCORD",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/642317?name=77293&mode=orpha&region=",
      "regulatory_id": "642317",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
        "(Tradename                        - 16/12/2022)",
        "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/642316?name=77293&mode=orpha&region=&status=all",
          "text": "PLERIXAFOR ACCORD",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/29073",
          "text": "ORPHA:29073 Multiple myeloma",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/223735",
          "text": "ORPHA:223735 Lymphoma",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/642317?name=77293&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Thiotepa Riemser",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/610636?name=77293&mode=orpha&region=",
      "regulatory_id": "610636",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Thiotepa Riemser(Tradename                        - 26/03/2021)",
        "(Tradename                        - 26/03/2021)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/610616?name=77293&mode=orpha&region=&status=all",
          "text": "Thiotepa Riemser",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/610636?name=77293&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "OFEV",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/692773?name=77293&mode=orpha&region=",
      "regulatory_id": "692773",
      "orpha_substance_code": "ORPHA:182095",
      "details": [
        "OFEV(Tradename                        - 13/07/2020)Disease(s) concernedORPHA:182095 Interstitial lung disease",
        "OFEV(Tradename                        - 13/07/2020)",
        "(Tradename                        - 13/07/2020)",
        "Disease(s) concernedORPHA:182095 Interstitial lung disease",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/412134?name=77293&mode=orpha&region=&status=all",
          "text": "OFEV",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/182095",
          "text": "ORPHA:182095 Interstitial lung disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/692773?name=77293&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "motixafortide",
      "substance_url": "/en/drug/substance/588874?name=77293&mode=orpha&region=&status=all",
      "substance_id": "588874",
      "regulatory_url": "/en/drug/regulatory/661036?name=77293&mode=orpha&region=",
      "regulatory_id": "661036",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "motixafortide(Medicinal product                        - 12/01/2024)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "motixafortide(Medicinal product                        - 12/01/2024)",
        "(Medicinal product                        - 12/01/2024)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/588874?name=77293&mode=orpha&region=&status=all",
          "text": "motixafortide",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/661036?name=77293&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
      "substance_url": "/en/drug/substance/589233?name=77293&mode=orpha&region=&status=all",
      "substance_id": "589233",
      "regulatory_url": "/en/drug/regulatory/589234?name=77293&mode=orpha&region=",
      "regulatory_id": "589234",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)",
        "(Medicinal product                        - 20/04/2020)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/589233?name=77293&mode=orpha&region=&status=all",
          "text": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/589234?name=77293&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
      "substance_url": "/en/drug/substance/589056?name=77293&mode=orpha&region=&status=all",
      "substance_id": "589056",
      "regulatory_url": "/en/drug/regulatory/589057?name=77293&mode=orpha&region=",
      "regulatory_id": "589057",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)",
        "(Medicinal product                        - 24/03/2020)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/589056?name=77293&mode=orpha&region=&status=all",
          "text": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/589057?name=77293&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "XENPOZYME",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/629911?name=77293&mode=orpha&region=",
      "regulatory_id": "629911",
      "orpha_substance_code": "ORPHA:618899",
      "details": [
        "XENPOZYME(Tradename                        - 31/08/2022)Disease(s) concernedORPHA:618899 Acid sphingomyelinase deficiency",
        "XENPOZYME(Tradename                        - 31/08/2022)",
        "(Tradename                        - 31/08/2022)",
        "Disease(s) concernedORPHA:618899 Acid sphingomyelinase deficiency",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/629877?name=77293&mode=orpha&region=&status=all",
          "text": "XENPOZYME",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/618899",
          "text": "ORPHA:618899 Acid sphingomyelinase deficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/629911?name=77293&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Burixafor",
      "substance_url": "/en/drug/substance/689505?name=77293&mode=orpha&region=&status=all",
      "substance_id": "689505",
      "regulatory_url": "/en/drug/regulatory/689915?name=77293&mode=orpha&region=",
      "regulatory_id": "689915",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Burixafor(Medicinal product                        - 22/10/2024)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Burixafor(Medicinal product                        - 22/10/2024)",
        "(Medicinal product                        - 22/10/2024)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/689505?name=77293&mode=orpha&region=&status=all",
          "text": "Burixafor",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/689915?name=77293&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Besilesomab",
      "substance_url": "/en/drug/substance/571152?name=77293&mode=orpha&region=&status=all",
      "substance_id": "571152",
      "regulatory_url": "/en/drug/regulatory/641081?name=77293&mode=orpha&region=",
      "regulatory_id": "641081",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Besilesomab(Medicinal product                        - 28/03/2022)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Besilesomab(Medicinal product                        - 28/03/2022)",
        "(Medicinal product                        - 28/03/2022)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/571152?name=77293&mode=orpha&region=&status=all",
          "text": "Besilesomab",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/641081?name=77293&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Besilesomab",
      "substance_url": "/en/drug/substance/571152?name=77293&mode=orpha&region=&status=all",
      "substance_id": "571152",
      "regulatory_url": "/en/drug/regulatory/641075?name=77293&mode=orpha&region=",
      "regulatory_id": "641075",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Besilesomab(Medicinal product                        - 28/03/2022)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Besilesomab(Medicinal product                        - 28/03/2022)",
        "(Medicinal product                        - 28/03/2022)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/571152?name=77293&mode=orpha&region=&status=all",
          "text": "Besilesomab",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/641075?name=77293&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Treosulfan",
      "substance_url": "/en/drug/substance/90799?name=77293&mode=orpha&region=&status=all",
      "substance_id": "90799",
      "regulatory_url": "/en/drug/regulatory/136690?name=77293&mode=orpha&region=",
      "regulatory_id": "136690",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Treosulfan(Medicinal product                        - 08/04/2015)Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Treosulfan(Medicinal product                        - 08/04/2015)",
        "(Medicinal product                        - 08/04/2015)",
        "Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/90799?name=77293&mode=orpha&region=&status=all",
          "text": "Treosulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/213500",
          "text": "ORPHA:213500 Rare ovarian cancer",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/136690?name=77293&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "busulfan",
      "substance_url": "/en/drug/substance/46335?name=77293&mode=orpha&region=&status=all",
      "substance_id": "46335",
      "regulatory_url": "/en/drug/regulatory/131973?name=77293&mode=orpha&region=",
      "regulatory_id": "131973",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "busulfan(Medicinal product                        - 21/04/1994)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "busulfan(Medicinal product                        - 21/04/1994)",
        "(Medicinal product                        - 21/04/1994)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/46335?name=77293&mode=orpha&region=&status=all",
          "text": "busulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/131973?name=77293&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    }
  ],
  "processing_timestamp": "2025-07-07T06:00:06.443437",
  "run_number": 1,
  "total_drugs_found": 16,
  "search_url": "https://www.orpha.net/en/drug?diseaseName=Chronic+visceral+acid+sphingomyelinase+deficiency&orphaCode=77293&name=77293&region=&mode=orpha&status=all",
  "search_params": {
    "diseaseName": "Chronic visceral acid sphingomyelinase deficiency",
    "orphaCode": "77293",
    "name": "77293",
    "region": "",
    "mode": "orpha",
    "status": "all"
  }
}